Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Market Cap	$33.06M	P/E Ratio	N/A
52W High	$20.20	52W Low	$5.12
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	75.1%	52W Position	31.0%
Overall Score	58	Value Score	60
Quality Score	34	Technical Score	80

EPS Current Est	$-11.36	EPS Next Est	$-4.18
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PASG	$9.80	-8.29%	77.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PASG	$9.80	-8.3%	77.35K
3
4
5
6

PASG

PASG

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Passage Bio Inc. Data in Excel

Get Passage Bio Inc. Data in Excel